Campbell Capital Management Inc. lowered its holdings in Bristol-Myers Squibb (NYSE:BMY) by 0.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 106,367 shares of the biopharmaceutical company’s stock after selling 914 shares during the period. Bristol-Myers Squibb makes up 3.1% of Campbell Capital Management Inc.’s investment portfolio, making the stock its 12th largest position. Campbell Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $6,715,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in BMY. United Bank grew its holdings in shares of Bristol-Myers Squibb by 5.4% in the third quarter. United Bank now owns 20,994 shares of the biopharmaceutical company’s stock worth $1,266,000 after acquiring an additional 1,080 shares during the period. Wealth Alliance lifted its position in shares of Bristol-Myers Squibb by 17.6% in the third quarter. Wealth Alliance now owns 11,889 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 1,776 shares in the last quarter. OLD Mission Capital LLC purchased a new stake in shares of Bristol-Myers Squibb in the third quarter worth about $234,000. Financial Advisory Service Inc. raised its position in Bristol-Myers Squibb by 6.5% during the third quarter. Financial Advisory Service Inc. now owns 11,671 shares of the biopharmaceutical company’s stock valued at $704,000 after purchasing an additional 712 shares during the period. Finally, Capital Advisory Group Advisory Services LLC raised its position in Bristol-Myers Squibb by 56.2% during the third quarter. Capital Advisory Group Advisory Services LLC now owns 1,648 shares of the biopharmaceutical company’s stock valued at $99,000 after purchasing an additional 593 shares during the period. Hedge funds and other institutional investors own 72.41% of the company’s stock.
BMY traded up $0.13 during trading hours on Thursday, reaching $62.19. 166,661 shares of the stock traded hands, compared to its average volume of 12,768,893. The firm’s fifty day simple moving average is $61.76 and its two-hundred day simple moving average is $65.68. The company has a market cap of $138.93 billion, a price-to-earnings ratio of -564.13, a PEG ratio of 1.00 and a beta of 0.67. Bristol-Myers Squibb has a fifty-two week low of $54.07 and a fifty-two week high of $67.16. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 3rd. Investors of record on Thursday, April 1st will be given a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date of this dividend is Wednesday, March 31st. Bristol-Myers Squibb’s payout ratio is presently 41.79%.
In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 25,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, March 22nd. The shares were sold at an average price of $62.20, for a total value of $1,555,000.00. Following the completion of the sale, the chief executive officer now directly owns 528,980 shares in the company, valued at $32,902,556. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.14% of the company’s stock.
Several research analysts recently issued reports on the company. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c” rating in a research note on Monday, March 8th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a research report on Tuesday. Finally, The Goldman Sachs Group upgraded Bristol-Myers Squibb from a “buy” rating to a “conviction-buy” rating in a research report on Tuesday, December 15th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Buy” and a consensus target price of $74.07.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Featured Story: What is a growth and income fund?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.